Ekf Diagnostics Holdings Plc · LSE:EKF
Ekf Diagnostics — FY2019 Earnings Presentation
15 slides from Ekf Diagnostics's earnings presentation, Mar 24, 2020
Slide 1: EKF Diagnostics Holdings plc Trading Update
EKF Diagnostics Holdings plc Trading Update 24 March 2020
Slide 2: Disclaimer
Disclaimer The information contained in these slides and the accompanying oral presentation (together, the “Presentation”) has been prepared by EKF Diagnostics Holdings plc (the “Company”). The Presentation is subject to updating, completion, revision and amendment without notice and as such it may
Slide 3: Agenda
Agenda Slide no. 4. Investment proposition 5. Financial highlights 6. Operational highlights 9. Commercial partnerships 10. Performance by Business Unit performance 14. Outlook
Slide 4: Investment proposition
Investment proposition • Strong performance throughout 2019 with excellent prospects for further growth in 2020 • Substantial net cash balances of £14.3m as of Friday 20 March 2020 • Positive cashflow • Minimal debt and well-controlled administrative overheads • New partnerships in contract manufact
Slide 5: Financial highlights
Financial highlights 44.9 42.5 41.6 • Revenues up 6% to £44.9m (2018: £42.5m) 38.6 37.1 • b-HB Liquicolor sales up £1.4m • 31.8 DiaSpect sales up £745k 30.0 • Quo-Test A1c sales up £557k 26.1 • Gross profit up 4% to £23.7m (2018: £22.7m) £M • Adjusted EBITDA* up 12% to £12.0m (2018: £10.7m) • Profit
Slide 6: Operational highlights
Operational highlights • Multi-million dollar contract manufacturing opportunity with Longhorn Vaccines and Diagnostics, USA for specimen collection tubes for COVID-19 testing. Contract awarded March 2020 • Longhorn VD own the only FDA cleared microbial nucleic acid storage and stabilisation device
Slide 7: Business Unit performance
Business Unit performance £20.6m revenues £13.8m revenues £6.1m revenues Significant growth in USA Large NGO and government contracts Investment in Elkhart facility to with b-HB LiquiColor in eastern Africa and Peru accommodate growth in contract manufacturing and fermentation Quo-Test distributor c
Slide 8: EKF Life Sciences
EKF Life Sciences • EKF Life Sciences Elkhart site at full capacity. Second manufacturing site required for fermentation and purification of enzymes • 24,000 sq. ft facility in South Bend, Indiana leased. First revenues expected in Q2 2020 • New facility to manufacture for existing and new customers
Slide 9: Commercial partnerships
Commercial partnerships • Signed preferred partnership agreement (PPA) with Mount Sinai Innovation Partners (MSIP), NYC • Agreement provides EKF with advanced access to innovative commercial opportunities arising from Mount Sinai Health System owned technologies managed by MSIP in the field of digit
Slide 10: Diabetes FY 2019
Diabetes FY 2019 • Revenues up £1,707k (9%) • Quo-Test up £557k (30%) Diabetes range • Large growth (+£300k) in Philippines Biosen • Working with several British CCGs to place analysers Quo-Lab A1c Quo-Test A1c • Quo-Lab down £251k (-10%) STAT-Site M b-HB • Biosen down £137k (-3%) b-HB LiquiColor •
Slide 11: Hematology FY 2019
Hematology FY 2019 • Revenues up £80k (1%) Hematology range • DiaSpect Tm up £742k (26%) DiaSpect Tm • Tender win in Egypt HemataStat II • Organic growth in India and South Africa Hemo Control • McKesson OEM in USA HemoPoint H2 UltraCrit • HemataStat up £388k (27%) • Hemo Control/H2 down £772k (-10%
Slide 12: Central Laboratory & Life Sciences FY 2019
Central Laboratory & Life Sciences FY 2019 Clinical chemistry, lab analysers, contract fermentation and enzymes • Revenues up £782k (14%) • Jordanian Army tender for Altair analysers Central Lab & Life Sciences • Life Sciences revenues up £456k (20%) Clinical chemistry • New fermentation business fr
Slide 13: Geographical performance
Geographical performance EMEA FY 2019 £15,498 £’000 APAC FY 2019 £4,867 £’000s AMERICAS Revenue FY 2020 £k FY 2019 £k +/- £k FY 2019 £22,178 APAC £4,867 £4,210 657 £’000 EMEA £15,498 £17,005 (1,507) AMERICAS £22,178 £20,369 1,809 13
Slide 14: 2020 Outlook
2020 Outlook Board expects continued strong growth from the business throughout 2020, particularly in the US • Q1 2020 trading performance in line with management expectations to date Business has benefited from the COVID-19 pandemic • c. $1m initial order placed by Longhorn VD in March 2020 and exp
Slide 15: Thanks
Thanks for your attention
EKF Diagnostics Holdings — FY2019 Earnings Presentation on 6ix